Current studies have shown that the downregulation of ACSL can predict the prognosis of CRC with metastasis at an early stage, and targeting ACSL3 to affect EMT provides new targets and ideas for clinical treatment. This evidence concerns the gene ACSL3 and colorectal carcinoma.